SecBot SecBot
6-K ·Filed Sep 14, 2026

GSK

GSK plc
BULLISH
Impact 7/10
Horizonmonths Processed2mo ago SEC0001654954-26-008318
Notable filing: 6-K
Actionable Insight ▲ Bullish

The data are strongly positive and derisk the first-line label expansion. Monitor for sNDA acceptance and FDA priority review status in Q4 2026. The WCLC Presidential Symposium presentation adds peer-reviewed credibility. GSK's oncology pipeline value is incrementally re-rated upward.

DirectionBullish
Confidencehigh
Horizonmonths

Drug in focus

GSK drug pipeline →

Jideytro

● Neutral Named in this 6-K
Impact
Phase
Approved (FDA); supported by the ARROS-1 phase I/II pivotal trial
Time to market
Approved and on the market in the US (approval 2026-07-22); additional global/regulatory filings and a first-line label expansion pending
Next catalyst
None dated

What to watchFor GSK shareholders this is a strategic-validation story, not a share-price catalyst: the approval news is out, and GSK's three most recent FDA approvals (Lynavoy, Exdensur, Blenrep) were each followed by slightly negative one-day moves (avg -2.19%), consistent with a mega-cap where single drugs barely move the tape. Watch the planned 2H-2026 first-line sNDA submission and commercial uptake of Jideytro, plus sister asset neladalkib (ALK inhibitor) with its own PDUFA later in 2026, the bigger single-stock binary for the Nuvalent deal thesis.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$50.05
T+0 close · Sep 14, 2026 · via day close
Latest settled
−6.25%
T+20 · $46.92 · next T+60 in 21d
Vs SPY
−8.52%
α at T+20
Latest observation
+3.50%
T+44 · FF3 residual α
  1. T+0 · Sep 14 $50.05entry
  2. T+1 · 2mo ago −0.08%α +0.38% · $50.01
  3. T+5 · 8w ago +2.06%α +1.95% · $51.08
  4. T+20 · 5w ago −6.25%α −8.52% · $46.92
  5. T+45 · todayOpen
  6. T+60 · in 21d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GSK announced positive registrational data from the ARROS-1 trial evaluating Jideytro (zidesamtinib) in first-line ROS1-positive NSCLC, showing a 94% objective response rate and 90% 12-month progression-free survival. The results support a planned supplemental NDA to the FDA in 2026 to expand the indication from second-line to first-line treatment, which could meaningfully expand the drug's addressable market and peak sales potential.

Key Facts

  • 94% objective response rate (ORR) in 94 TKI-naïve patients at 15.2 months median follow-up
  • 90% of patients progression-free at 12 months; median PFS not yet reached
  • 70% of patients with measurable brain metastases achieved complete intracranial clearance
  • Only 1% treatment discontinuation rate due to TRAEs; 11% dose reduction rate
  • US regulatory submission (sNDA) for first-line indication planned in 2026
  • Drug already FDA-approved for second-line ROS1-positive NSCLC (July 2026)
  • Asset acquired via Nuvalent acquisition completed July 2026

Financial Impact

Expanding Jideytro to first-line ROS1-positive NSCLC could address an estimated ~50,000 new annual diagnoses worldwide (2% of NSCLC). First-line label typically captures 2-3x the peak sales of second-line only. No specific revenue figures provided in filing.

revenuemarket sharepipeline value

Risk Factors

  • Regulatory risk: FDA may require additional data or raise concerns about single-arm trial design for first-line approval
  • Competitive risk: existing ROS1 TKIs (entrectinib, repotrectinib, taletrectinib) may have overlapping profiles
  • Commercial execution risk: GSK must build NSCLC commercial infrastructure against established players

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
44% bullish (32 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-008318
Document: 0001654954-26-008318-index-headers.html0001654954-26-008318
Document: 0001654954-26-008318-index.html0001654954-26-008318
Document: 0001654954-26-008318.txt0001654954-26-008318

US Market Status

Market Closed · Opens Wed (10h 30m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 14, 2026